testing positive for a germline BRCA1 variant. Germline BRCA 1 and BRCA 2 test results were available for all 450 men. These revealed 27 germline BRCA2 variants (6%), but only two germline BRCA1 ...

As a young breast cancer survivor with a BRCA1-positive diagnosis, I faced tough choices. Ultimately, I chose to undergo a laparoscopic prophylactic oophorectomy, a decision rooted in my ...

The former NBC news anchor, 49, revealed last month in an Instagram post that she had tested positive for the BRCA1 gene mutation, putting her at a higher risk for breast and ovarian cancer.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

testing positive for a germline BRCA1 variant. Germline BRCA 1 and BRCA 2 test results were available for all 450 men. These revealed 27 germline BRCA2 variants (6%), but only 2 germline BRCA1 ...

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

While Brandy, 28, didn’t test positive for the BRCA gene mutation, it was revealed Cassidy, 27, had the gene. According to the National Cancer Institute, “The risks of developing breast and ...

BRCA mutations also raise your chances for ovarian ... Research suggests about only 10% to 20% of cases are HER2-positive. This means there’s a change in the HER2 gene that makes breast cells ...

BRCA-positive breast cancer after first-line chemotherapy. Helen Knight, director of medicines evaluation at NICE, said that the guidance “addresses a significant need by giving people with ...

[47,48] Although MRI is an effective surveillance modality in BRCA mutation carriers–especially in younger women–a significant proportion of women are still found to have node positive breast ...

Cancer is a disease that profoundly impacts lives, often leaving individuals and families with uncertainty and fear. However, ...

Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations ... have ...